Legend Biotech Corporation (FRA:9LB)

Market Cap	2.98B -44.6%
Revenue (ttm)	1.11B +59.5%
Net Income	-80.09M
EPS	-0.44
Shares Out	n/a
PE Ratio	n/a
Forward PE	27.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	488
Open	15.50
Previous Close	15.30
Day's Range	15.10 - 16.00
52-Week Range	13.80 - 31.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Legend Biotech

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 3,200
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9LB

Financial Performance

In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 20, 2026

Data Sources Report a data error